Outcomes of @entity1 With Acute  @entity583 Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and  Dual  Antiplatelet Therapy: A Comparison of XXXX Versus @entity3076 From the TRANSLATE-ACS Study.

@entity1 @entity3076 @entity859 @entity548 @entity301 @entity1397 @entity117 @entity583 @entity6629
OBJECTIVES: The purpose of this study was to determine whether @entity548 risk varies depending on which P2Y12 receptor inhibitor agent is used. BACKGROUND: Prior studies have shown significant @entity548 risk among @entity1 treated with triple therapy (i.e., oral anticoagulant, P2Y12 receptor inhibitor, and @entity117 ). METHODS: We evaluated @entity1 with acute @entity583 ( @entity583 ) treated with percutaneous coronary intervention (PCI) at 233 hospitals in the United States enrolled in the TRANSLATE-ACS (Treatment with @entity859 Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute @entity301 ) study  (April 2010 to October 2012). Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) @entity548 , stratifying by whether or not @entity548 was  associated with rehospitalization among @entity1 discharged on @entity117  + anticoagulant  + @entity1397 (triple-C), @entity117  + anticoagulant  + @entity3076 (triple-P), @entity117  + @entity1397 (dual-C), or @entity117  + @entity3076 (dual-P). RESULTS: Of 11,756 @entity583 @entity1 , 526 (4.5%) were discharged on triple-C, 91 (0.8%) on triple-P, 7,715 (66%) on dual-C, and 3,424 (29%) on dual-P. Compared with dual-therapy @entity1 , triple-therapy @entity1 had significantly higher any BARC-defined @entity548 . @entity6629 was associated with a greater risk of any BARC-defined @entity548 events compared with triple-C. This finding was driven mostly by an increased risk of @entity548 events that were @entity1 -reported only and did not require rehospitalization. There were no significant differences in @entity548 requiring rehospitalization between the triple-P and -C groups. CONCLUSIONS: Among @entity583 @entity1 , the addition of an oral anticoagulant was associated with a significantly greater risk of any BARC-defined @entity548 relative to dual antiplatelet therapy, regardless of which P2Y12 receptor inhibitor was selected. Among @entity1 on triple therapy, @entity3076 use was associated with higher @entity1 -reported-only @entity548 , but not @entity548 requiring rehospitalization, than @entity1397 -treated @entity1 .
